Skip to main content

Day: May 3, 2021

uniQure to Participate in Multiple Upcoming Industry Conferences in May

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 03, 2021 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:7th Annual Truist Securities Life Sciences Summit, May 4 – 5, 2021Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, May 4.American Society of Gene and Cell Therapy (ASGCT) Virtual 2021, May 11 – 14, 2021uniQure will have a significant presence at ASGCT with five data presentations, of which two are oral presentations including:“Clinical Outcomes in Patients With and Without Pre-existing Neutralizing Antibodies to the...

Continue reading

Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates

– Acute safety data from the first cohort in the DesCAARTes™ trial announced today; no dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021 – – PLA2R-CAART announced as a new development program for patients with PLA2R-associated membranous nephropathy; pre-IND meeting with FDA planned in the second half of 2021 – – MuSK-CAART Investigational New Drug (IND) application submission planned for the second half of 2021 – PHILADELPHIA, May 03, 2021 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today reported financial results for the first quarter ended March 31, 2021, and provided new pipeline...

Continue reading

Akoustis Locks Process Flow for Second Wafer Level Package for XBAW Filters

New Packaging Solution Addresses the Small Form Factor Requirements for 5G Mobile and WiFi 6E Devices Packages Will Be Manufactured Both In-House and in Outside Supply Chain to Provide Rapid Prototyping and Flexible Capacity Micro Package Compatible Across XBAW Filter Product Line for 5G Mobile, WiFi and Network InfrastructureCharlotte, N.C., May 03, 2021 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that it has locked the process flow for its second chip scale package (CSP). The new CSP technology supports the Company’s XBAW® filter products across the 5G mobile, WiFi mobile and CPE and network infrastructure markets. The...

Continue reading

Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting

Flavia Borellini, Ph.D., Distinguished Precision Oncology Drug Development Leader, Joins Existing Board Members Elizabeth McKee Anderson and Neil Exter as Class I Director Nominees REDWOOD CITY, Calif., May 03, 2021 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today highlights the nomination of a slate of three individuals for election/reelection to its board of directors. Flavia Borellini, Ph.D. has been nominated by the company’s board of directors for election as a first-time Class I director, joining current Class I directors Elizabeth McKee Anderson and Neil Exter, who were nominated for reelection. These nominees will be voted on at the June 22, 2021 Revolution Medicines...

Continue reading

Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp

SALT LAKE CITY, May 03, 2021 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement to sell select operating assets and intellectual property (IP), including the Vectra® test, from Myriad Autoimmune’s business unit to Labcorp (NYSE: LH) for $150 million in cash. Labcorp is a leading global life sciences company and one of the nation’s largest laboratory service providers. “Our agreement with Labcorp meets our goals of ensuring broad access to the Vectra® test for patients, ensuring a good home for our teammates, and delivering strong value for our shareholders,” said Paul J. Diaz, president and CEO of Myriad Genetics. “While we are strong believers in the future growth prospects for Vectra, this divestiture will allow...

Continue reading

GameStop Expands Fulfillment Network with New Facility in York, Pennsylvania

New 700,000 Square Foot Site to Support Transformation GRAPEVINE, Texas, May 03, 2021 (GLOBE NEWSWIRE) — GameStop Corp. (NYSE: GME) (“GameStop” or the “Company”) today announced the expansion of its North American fulfillment network through its entry into a lease of a 700,000 square foot fulfillment center in York, Pennsylvania. This facility is expected to be operational by the fourth quarter of 2021 and will support ecommerce and fulfillment needs. The Company expects its fulfillment center in York, Pennsylvania will position it to grow product offerings and expedite shipping across the east coast.  About GameStop GameStop, a Fortune 500 company headquartered in Grapevine, Texas, is a leading specialty retailer offering games and entertainment products through its ecommerce properties and thousands of stores. Visit www.GameStop.com to...

Continue reading

Partners Value Split Corp. to Redeem Its Class AA Preferred Shares, Series 7

TORONTO, May 03, 2021 (GLOBE NEWSWIRE) — Partners Value Split Corp. (the “Company”) announced today its intention to redeem all 4,000,000 of its Class AA Preferred Shares, Series 7 (“Preferred Shares, Series 7”) for cash on May 20, 2021 (the “Redemption Date”) in accordance with the terms of the Preferred Shares, Series 7. The redemption price per Preferred Shares, Series 7 will be equal to C$25.50 plus accrued and unpaid dividends of C$0.30220 per share to May 20, 2021 representing a total redemption price of C$25.8022 per share (the “Redemption Price”). Notice will be delivered to holders of the Preferred Shares, Series 7 in accordance with the terms of the Preferred Shares, Series 7. From and after the Redemption Date, the Preferred Shares, Series 7 will cease to be entitled to dividends or any other participation in any distribution...

Continue reading

Statkraft AS: Release of first quarter results 2021

Statkraft discloses first quarter results 2021 on Thursday 6 May 2021 at 08:00 a.m. CEST. The material will be available on Statkraft’s website www.statkraft.com/ir and Oslo Stock Exchange’s news service www.newsweb.no. Live webcast09:00 a.m. CEST: Statkraft presents the results in a live webcast at www.statkraft.com. The presentation will be held in English. Contact:Arild Ratikainen, Investor Contact, tlf.: +47 971 74 132, e-mail: arild.ratikainen@statkraft.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Continue reading

Flywire Files Registration Statement with SEC for Proposed Initial Public Offering

BOSTON, May 03, 2021 (GLOBE NEWSWIRE) — Flywire Corporation (“Flywire”), a global payments enablement and software company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Flywire intends to list its common stock on the Nasdaq Global Market under the ticker symbol “FLYW.” Goldman Sachs & Co. LLC, J.P. Morgan, Citigroup and BofA Securities will act as lead book-running managers for the proposed offering. The offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: Goldman Sachs...

Continue reading

USI Insurance Services Completes Acquisition of Insurance Business Offered Through Northwest Insurance Services

New Partnership Expands USI’s Commercial, Employee Benefit and Personal Risk ExpertiseVALHALLA, N.Y. and WARREN, Pa., May 03, 2021 (GLOBE NEWSWIRE) — USI Insurance Services (“USI”), a world leader in risk management, employee benefit and retirement plan consulting, today announced the completion of its acquisition of the insurance business offered through Northwest Insurance Services from Northwest Bank, a subsidiary of Northwest Bancshares, Inc. (NASDAQ: NWBI). Northwest Insurance Services is a wholly-owned subsidiary of Northwest Bank, offering property and casualty, life, disability and long-term care insurance, as well as group health, life and disability employee benefits. Northwest Bank’s President and CEO, Ron Seiffert stated: “In searching for the right partner for our insurance business,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.